MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia

Resistance to tyrosine kinase inhibitors (TKIs) remains a clinical challenge in Ph-positive variants of chronic myeloid leukemia. We provide mechanistic insights into a previously undisclosed MEK1/2/BCR::ABL1/BCR/ABL1-driven signaling loop that may determine the efficacy of arsenic trioxide (ATO) in...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazzera, Laura, Abeltino, Manuela, Lombardi, Guerino, Cantoni, Anna Maria, Jottini, Stefano, Corradi, Attilio, Ricca, Micaela, Rossetti, Elena, Armando, Federico, Peli, Angelo, Ferrari, Anna, Martinelli, Giovanni, Scupoli, Maria Teresa, Visco, Carlo, Bonifacio, Massimiliano, Ripamonti, Alessia, Gambacorti-Passerini, Carlo, Bonati, Antonio, Perris, Roberto, Lunghi, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400427/
https://www.ncbi.nlm.nih.gov/pubmed/37386079
http://dx.doi.org/10.1038/s41375-023-01940-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400427/
https://www.ncbi.nlm.nih.gov/pubmed/37386079
http://dx.doi.org/10.1038/s41375-023-01940-x

Ejemplares similares